Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916216 | 1.00 | KMT2A (0.38) | KMT2AEPHX2HRH3BTKCA12 | |
| SCHEMBL915115 | 0.87 | KMT2A (0.37) | KMT2AEPHX2HRH3LMNA | |
| SCHEMBL915110 | 0.87 | KMT2A (0.37) | KMT2AEPHX2HRH3LMNA | |
| SCHEMBL6645183 | 0.79 | KMT2A (0.58) | KMT2AEPHX2BTKCA1CA2 | |
| SCHEMBL16732777 | 0.79 | KMT2A (0.58) | KMT2AEPHX2BTKCA1CA2 | |
| SCHEMBL23611929 | 0.79 | KMT2A (0.58) | KMT2AEPHX2BTKCA1CA2 | |
| SCHEMBL16755142 | 0.79 | KMT2A (0.58) | KMT2AEPHX2BTKCA1CA2 | |
| SCHEMBL16755143 | 0.79 | KMT2A (0.58) | KMT2AEPHX2BTKCA1CA2 | |
| SCHEMBL925789 | 0.78 | KMT2A (0.32) | KMT2ALMNA | |
| SCHEMBL925792 | 0.77 | KMT2A (0.54) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885EPHX2 579/4885HRH3 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.